{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:01:54Z","timestamp":1771002114701,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1684\/bdc.2012.1596","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:07:50Z","timestamp":1565726870000},"page":"627-634","source":"Crossref","is-referenced-by-count":3,"title":["Carcinome r\u00e9nal : \u00e9tat des lieux de la prise en charge des m\u00e9tastases c\u00e9r\u00e9brales"],"prefix":"10.1016","volume":"99","author":[{"given":"Corine","family":"Teghom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Menei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Medioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9za","family":"Elaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Combe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2012.1596_bib0005","doi-asserted-by":"crossref","DOI":"10.4065\/82.10.1271","article-title":"Central nervous system tumors","author":"Buckner","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1684\/bdc.2012.1596_bib0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.seminoncol.2006.06.009","article-title":"The pathology of renal epithelial neoplasms","volume":"33","author":"Reuter","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.urology.2008.09.022","article-title":"Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma","volume":"73","author":"Zini","year":"2009","journal-title":"Urology"},{"key":"10.1684\/bdc.2012.1596_bib0025","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"10.1684\/bdc.2012.1596_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000315543","article-title":"Kidney cancer pathology in the new context of targeted therapy","volume":"78","author":"Allory","year":"2011","journal-title":"Pathobiology"},{"key":"10.1684\/bdc.2012.1596_bib0040","first-page":"4136","article-title":"Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the Von Hippel-Lindau tumor suppressor protein","volume":"61","author":"Yu","year":"2001","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2012.1596_bib0045","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor-1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1684\/bdc.2012.1596_bib0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/jso.10302","article-title":"Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth","volume":"84","author":"Shin Lee","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","article-title":"Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the Phase III Record-1 Study","volume":"48","author":"Calvo","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1596_bib0065","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2012.1596_bib0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1596_bib0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1596_bib0080","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/cncr.24241","article-title":"Sequential therapy in renal cell carcinoma","volume":"115","author":"Escudier","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1464-410x.1999.00202.x","article-title":"Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy","volume":"84","author":"Ljungberg","year":"1999","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1596_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ctrv.2011.06.008","article-title":"Brain metastases from renal cell carcinoma. Should we change the current standard?","volume":"38","author":"Remon","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2012.1596_bib0095","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/cncr.23769","article-title":"Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival","volume":"113","author":"Shuch","year":"2008","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1215\/15228517-2008-010","article-title":"What is the risk of intracranial bleeding during anti-VEGF therapy?","volume":"10","author":"Carden","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0105","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.20167","article-title":"Stereotactic radiosurgery for multiple brain metastases from breast carcinoma","volume":"100","author":"Muacevic","year":"2004","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/JCO.1984.2.3.169","article-title":"Brain metastases in patients with renal cell carcinoma: prognosis and treatment","volume":"2","author":"Decker","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","article-title":"The seed and soil hypothesis: vascularisation and brain metastases","volume":"3","author":"Fidler","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation.","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat Med"},{"key":"10.1684\/bdc.2012.1596_bib0125","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1684\/bdc.2012.1596_bib0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0360-3016(03)00818-6","article-title":"Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study","volume":"58","author":"Cannady","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1684\/bdc.2012.1596_bib0135","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"Jama"},{"key":"10.1684\/bdc.2012.1596_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11060-009-9839-y","article-title":"Management of brain metastases: the indispensable role of surgery","volume":"92","author":"Al-Shamy","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1684\/bdc.2012.1596_bib0145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.410330605","article-title":"Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?","volume":"33","author":"Vecht","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1684\/bdc.2012.1596_bib0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3171\/jns.1993.79.2.0210","article-title":"Surgical treatment of multiple brain metastases","volume":"79","author":"Bindal","year":"1993","journal-title":"J Neurosurg"},{"key":"10.1684\/bdc.2012.1596_bib0155","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/00006123-199805000-00054","article-title":"Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors","volume":"42","author":"Sawaya","year":"1998","journal-title":"Neurosurgery"},{"key":"10.1684\/bdc.2012.1596_bib0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0090-4295(99)80413-0","article-title":"Surgical resection of brain metastases from renal cell carcinoma in 50 patients","volume":"47","author":"Wronski","year":"1996","journal-title":"Urology"},{"key":"10.1684\/bdc.2012.1596_bib0165","first-page":"186","article-title":"Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases","volume":"73","author":"Marko","year":"2010","journal-title":"Surg Neurol"},{"key":"10.1684\/bdc.2012.1596_bib0170","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.1996.14.4.1085","article-title":"Linear accelerator-based stereotaxic radiosurgery for brain metastases: the influence of number of lesions on survival","volume":"14","author":"Joseph","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3171\/jns.1999.91.1.0035","article-title":"Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter","volume":"91","author":"Muacevic","year":"1999","journal-title":"J Neurosurg"},{"key":"10.1684\/bdc.2012.1596_bib0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-009-0099-7","article-title":"The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"Linskey","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1684\/bdc.2012.1596_bib0185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1684\/bdc.2012.1596_bib0200","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"J Hypertens"},{"key":"10.1684\/bdc.2012.1596_bib0205","article-title":"Phase II of sunitinib in renal cell cancer with untreated brain metastases: ASCO 2011, Chicago","volume":"29","author":"Chevreau","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-010-0200-2","article-title":"Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer","volume":"100","author":"De Braganca","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1684\/bdc.2012.1596_bib0215","doi-asserted-by":"crossref","unstructured":"Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117 : 501-509.","DOI":"10.1002\/cncr.25452"},{"key":"10.1684\/bdc.2012.1596_bib0220","doi-asserted-by":"crossref","unstructured":"Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116 : 1272-1280.","DOI":"10.1002\/cncr.24864"},{"key":"10.1684\/bdc.2012.1596_bib0225","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11523-007-0050-9","article-title":"Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient","volume":"2","author":"Medioni","year":"2007","journal-title":"Target Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2012.1596_bib0235","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1634\/theoncologist.12-7-884","article-title":"Multidisciplinary management of brain metastases","volume":"12","author":"Eichler","year":"2007","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2012.1596_bib0240","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (avastin), a humanized anti-vegf monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1684\/bdc.2012.1596_bib0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ctrv.2000.0194","article-title":"The blood-brain barrier and oncology: new insights into function and modulation","volume":"26","author":"Bart","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2012.1596_bib0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s004010000180","article-title":"Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme","volume":"100","author":"Liebner","year":"2000","journal-title":"Acta Neuropathol"},{"key":"10.1684\/bdc.2012.1596_bib0255","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2012.1596_bib0260","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1596_bib0270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.2007.13.5814","article-title":"Brain metastases in patients with renal cell cancer receiving new targeted treatment","volume":"26","author":"Helgason","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0275","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/annonc\/mdp411","article-title":"Incidence of brain metastases in renal cell carcinoma treated with sorafenib","volume":"21","author":"Massard","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0280","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1002\/cncr.26138","article-title":"Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma","volume":"117","author":"Verma","year":"2011","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0285","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/annonc\/mdm275","article-title":"Complete cerebral response with sunitinib for metastatic renal cell carcinoma","volume":"18","author":"Medioni","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-008-9676-4","article-title":"Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma","volume":"91","author":"Valcamonico","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1684\/bdc.2012.1596_bib0295","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000251193","article-title":"Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib","volume":"83","author":"Zeng","year":"2009","journal-title":"Urol Int"},{"key":"10.1684\/bdc.2012.1596_bib0300","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/cncr.23857","article-title":"Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery","volume":"113","author":"Samlowski","year":"2008","journal-title":"Cancer"},{"key":"10.1684\/bdc.2012.1596_bib0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1684\/bdc.2012.1596_bib0310","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/JTO.0b013e318219a973","article-title":"Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases","volume":"6","author":"Novello","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2012.1596_bib0315","unstructured":"Weikert S, Kempkensteffen C, Busch J, et al. Sequential MTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol Apr 22 [Epub ahead of print]."},{"key":"10.1684\/bdc.2012.1596_bib0320","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1464-410X.2009.08972.x","article-title":"Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review","volume":"105","author":"Choueiri","year":"2010","journal-title":"BJU Int"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T23:59:02Z","timestamp":1721606342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511530429X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S000745511530429X"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2012.1596","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}